Tasly gets Chinese rights to Lilly's diabetes candidate

Eli Lilly and Co. (NYSE:LLY) granted the Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. subsidiary of Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) exclusive rights to develop and commercialize LY-292...